Coronavirus COVID-19: News and Measures concerning the Life Science Industry

by Janine Reudt-Demont

Currently, the global impact of the COVID-19 pandemic is rapidly escalating. The Federal Council has taken various measures that affect people and companies active in the life science industry in particular, such as the restricted distribution of certain medicines. Almost on a daily basis, other authorities such as Swissmedic or the Federal Office of Public Health issue guidelines, for instance on how to deal with ongoing clinical trials, or on the regulations applicable to the marketing of hand sanitizers.

This newsletter is intended to help keep track of the various measures and guidelines that are relevant to the life science industry (status: 28 March 2020).